< Back to previous page

Publication

Motion management during SBRT for oligometastatic cancer

Journal Contribution - Journal Article

Subtitle:Results of a prospective phase II trial

PURPOSE: To optimize the local control of stereotactic body radiotherapy (SBRT) using the Vero-SBRT system and respiratory motion management in patients with oligometastatic cancer.

MATERIALS AND METHODS: Patients with five or less metastases were eligible. In metastases with significant motion, a fiducial was implanted for Vero dynamic tracking. For other metastases an internal target volume (ITV) was defined to encompass the respiratory tumor trajectory. A dose of 50Gy in 10 fractions was prescribed on the 80% isodose line.

RESULTS: We treated 87 metastases in 44 patients, with colorectal cancer as the most common primary origin (65.9%). Metastatic sites were mainly lung (n=62) and liver (n=17). Twenty-seven metastases were treated with dynamic tracking, the remaining 60 using the ITV-concept. Three patients (7%) experienced grade ⩾3 toxicity. After a median follow-up of 12months, the overall one-year local control (LC) amounted to 89% (95% CI 77-95%), with corresponding values of 90% and 88% for the metastases irradiated with the ITV-approach and dynamic tracking, respectively. Median progression-free survival reached 6.5months, one-year overall survival 95%.

CONCLUSIONS: SBRT with proper respiratory motion management resulted in a high LC and an acceptable toxicity profile in oligometastatic cancer patients.

Journal: Radiotherapy & Oncology
ISSN: 0167-8140
Issue: 3
Volume: 119
Pages: 519-524
Publication year:2016
  • ORCID: /0000-0003-4556-5681/work/62081763
  • ORCID: /0000-0002-3601-3212/work/91494630
  • ORCID: /0000-0003-1296-4627/work/71403252
  • ORCID: /0000-0002-5717-7136/work/61831492
  • ORCID: /0000-0001-9108-610X/work/60612495
  • Scopus Id: 84969941197
  • WoS Id: 000380075400023
  • DOI: https://doi.org/10.1016/j.radonc.2016.04.020
CSS-citation score:1
Authors:International